Cover Image
市場調查報告書

混合型血脂異常:開發中產品分析

Mixed Dyslipidemia - Pipeline Review, H1 2016

出版商 Global Markets Direct 商品編碼 200976
出版日期 內容資訊 英文 69 Pages
訂單完成後即時交付
價格
Back to Top
混合型血脂異常:開發中產品分析 Mixed Dyslipidemia - Pipeline Review, H1 2016
出版日期: 2016年05月31日 內容資訊: 英文 69 Pages
簡介

血漿膽固醇或中性脂肪(TG),以及雙方上昇,或是高比重脂蛋白(LDL)的水準降低,都是引起血脂異常症的原因。而膽固醇和TG雙方同時上升,更被稱為混合型血脂異常。TG的水準上升關係到急性胰炎的發病。此外LDL水準上升,更是造成眼瞼黃色瘤和角膜環,以及腱·肘·膝·中指關節肌腱黃色瘤的要素。這個疾病的病因有許多的主要要素(遺傳性)及次要要素(生活習慣)。治療方法有風險評估和生活習慣的改善(運動,飲食改善),使用HMG-CoA還原酶抑制劑(statins)的LDL膽固醇標靶治療等。針對高TG和低HDL膽固醇則使用菸鹼酸治療。

本報告提供全球各國治療混合型血脂異常所用的開發中產品之開發情形相關分析,提供您開發中產品的最新趨勢,及臨床實驗的各階段產品一覽,主要企業簡介,主要藥物概要(產品概要,功能機制,研究開發(R&D)的發展情形),最新的產業趨勢等調查資訊。

簡介

  • 分析範圍

混合型血脂異常概要

治療藥的開發

  • 混合型血脂異常開發中產品:概要
  • 混合型血脂異常開發中產品:比較分析

各企業開發中的混合型血脂異常治療藥

開發中產品的概要

  • 後期階段的產品
  • 臨床實驗階段的產品
  • 初期階段的產品

混合型血脂異常治療藥:開發中的產品一覽(各企業)

混合型血脂異常開發治療藥的企業

  • Amgen Inc.
  • CymaBay Therapeutics, Inc.
  • Hanmi Pharmaceuticals, Co. Ltd.
  • Matinas BioPharma Holdings, Inc.
  • Pfizer Inc.
  • Thetis Pharmaceuticals LLC

混合型血脂異常:治療藥的評估

  • 單劑治療藥的情況
  • 標的別
  • 各行動機制
  • 各投藥法
  • 各治療分類

藥物簡介

混合型血脂異常治療藥:最新的藥物簡介

混合型血脂異常治療藥:暫停開發的產品

混合型血脂異常治療藥:中止開發的產品

混合型血脂異常相關產品的開發里程碑

  • 值得注意的最新趨勢·新聞稿

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8141IDB

Summary

Global Markets Direct's, 'Mixed Dyslipidemia - Pipeline Review, H1 2016', provides an overview of the Mixed Dyslipidemia pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Mixed Dyslipidemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Mixed Dyslipidemia and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Mixed Dyslipidemia
  • The report reviews pipeline therapeutics for Mixed Dyslipidemia by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Mixed Dyslipidemia therapeutics and enlists all their major and minor projects
  • The report assesses Mixed Dyslipidemia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Mixed Dyslipidemia

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Mixed Dyslipidemia
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Mixed Dyslipidemia pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Mixed Dyslipidemia Overview
  • Therapeutics Development
    • Pipeline Products for Mixed Dyslipidemia - Overview
  • Mixed Dyslipidemia - Therapeutics under Development by Companies
  • Mixed Dyslipidemia - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Mixed Dyslipidemia - Products under Development by Companies
  • Mixed Dyslipidemia - Companies Involved in Therapeutics Development
    • Amgen Inc.
    • CymaBay Therapeutics, Inc.
    • Hanmi Pharmaceuticals, Co. Ltd.
    • Matinas BioPharma Holdings, Inc.
    • Pfizer Inc.
    • Thetis Pharmaceuticals LLC
  • Mixed Dyslipidemia - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • bococizumab - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • evolocumab - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • HCP-1105 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • IONIS-ANGPTL3LRx - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • MAT-9001 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • MBX-8025 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • TP-452 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Mixed Dyslipidemia - Recent Pipeline Updates
  • Mixed Dyslipidemia - Dormant Projects
  • Mixed Dyslipidemia - Discontinued Products
  • Mixed Dyslipidemia - Product Development Milestones
    • Featured News & Press Releases
      • May 24, 2016: New study results show cholesterol-lowering medication, Repatha (evolocumab), lowers LDL-C when self-administered in at-home setting
      • Apr 01, 2016: Pfizer Announces Positive Topline Results From Second Phase 3 Lipid-Lowering Study Evaluating Bococizumab
      • Mar 16, 2016: Amgen Wins Patent Case On Repatha (Evolocumab)
      • Nov 18, 2015: NICE issues draft guidance on evolocumab for lipid disorder
      • Mar 30, 2014: Data From Phase 3 Pivotal Studies Show Amgen's Novel Investigational Cholesterol-Lowering Medication Evolocumab Significantly Reduced LDL Cholesterol In Statin Intolerant Patients And In Patients On Statins
      • Mar 29, 2014: New Detailed Data from Three Phase 3 Pivotal Studies Show Amgen's Novel Investigational Cholesterol-Lowering Medicine Evolocumab Significantly Reduced LDL Cholesterol By 55-66 Percent Compared To Placebo In Patients With High Cholesterol
      • Dec 19, 2013: Amgen Announces Positive Top-Line Results From 52-Week Phase 3 DESCARTES Study Of Evolocumab In Patients With High Cholesterol
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Mixed Dyslipidemia, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Development, H1 2016
  • Products under Development by Companies, H1 2016
  • Mixed Dyslipidemia - Pipeline by Amgen Inc., H1 2016
  • Mixed Dyslipidemia - Pipeline by CymaBay Therapeutics, Inc., H1 2016
  • Mixed Dyslipidemia - Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H1 2016
  • Mixed Dyslipidemia - Pipeline by Matinas BioPharma Holdings, Inc. , H1 2016
  • Mixed Dyslipidemia - Pipeline by Pfizer Inc., H1 2016
  • Mixed Dyslipidemia - Pipeline by Thetis Pharmaceuticals LLC, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Stage and Target, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Mixed Dyslipidemia Therapeutics - Recent Pipeline Updates, H1 2016
  • Mixed Dyslipidemia - Dormant Projects, H1 2016
  • Mixed Dyslipidemia - Discontinued Products, H1 2016

List of Figures

  • Number of Products under Development for Mixed Dyslipidemia, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Targets, H1 2016
  • Number of Products by Stage and Targets, H1 2016
  • Number of Products by Mechanism of Actions, H1 2016
  • Number of Products by Stage and Mechanism of Actions, H1 2016
  • Number of Products by Routes of Administration, H1 2016
  • Number of Products by Stage and Routes of Administration, H1 2016
  • Number of Products by Molecule Types, H1 2016
  • Number of Products by Stage and Molecule Types, H1 2016
Back to Top